Identification of disulfidptosis-related prognostic biomarkers associated with CD4 + and CD8 + T cells infiltration for sarcoma by integrating bioinformatic analysis and experimental validation.

Wenliang Tan, Xi Zhou, Ting Wang, Shuanghua Wu, Ting Mo, Zhiqin Xie, Yang Xie

Abstract read

In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenliang TanCenter of Hepatobiliary and Pancreatic Surgery, Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, 412000, China.

Xi ZhouCenter of Hepatobiliary and Pancreatic Surgery, Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, 412000, China.

Ting WangRehabilitation Medicine Department, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, 412000, Zhuzhou, China.

Shuanghua WuIntensive Care Medicine Department, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, 412000, Zhuzhou, China.

Ting MoRehabilitation Medicine Department, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, 412000, Zhuzhou, China.

Zhiqin XieCenter of Hepatobiliary and Pancreatic Surgery, Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, 412000, China. xiezhiqin@csu.edu.cn.

Yang XieDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha, 410008, China. xy11105@csu.edu.cn.

Funding

National Natural Science Foundation of China 82103221National Natural Science Foundation of China 82304794

6 · The paper itself

Abstract

Recently identified, disulfidptosis represents a novel form of cell death triggered by disulfide stress. The impact of disulfidptosis-related gene (DRG) patterns on the clinical prognosis of sarcoma, however, remains unexplored. In this study, two prognostic genes related to DRGs, CCDC69 and HMGB3, were found, and a prognosis prediction models of sarcoma subtypes was developed. KM and AUC analysis revealed the remarkable prediction accuracy of these models. CCDC69 and HMGB3 are differentially expressed, which is closely related to survival results and the existence of a large number of immune infiltrating cells in cancers. The mIHC analysis showed that compared with normal tissues, the levels of HMGB3 in sarcoma tissues was higher, and the high expression of HMGB3 was related to the increased infiltration of CD4 + and CD8 + T cells. This study reveals the potential of combining CCDC69 and HMGB3 with DRGs as a new biomarker for the clinical diagnosis and a potential immunotherapy targets for sarcoma.

Indexed as

CCDC69DisulfidptosisHMGB3PrognosisSarcoma

Identifiers

PMID40627276

DOI10.1007/s12672-025-03127-5

PMCPMC12237837

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.